January 29, 2020 10:39 AM ESTUpdated 06:05 PM

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year

Amber Tong

In the leadup to a “major expected” Phase III trial readout for asciminib in third-line chronic myelogenous leukemia, Novartis has unceremoniously removed a planned filing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

Roivant brings rare disease program closer as Immunovant CEO retires

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No­var­tis re­thinks CML strat­e­gy for next-gen al­losteric drug due for a piv­otal read­out lat­er this year

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year